{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:06Z","timestamp":1792065366739,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":223,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.bjid.2012.10.009","type":"journal-article","created":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T05:03:01Z","timestamp":1357016581000},"page":"74-81","source":"Crossref","is-referenced-by-count":43,"title":["Challenges in the development of drugs for the treatment of tuberculosis"],"prefix":"10.1016","volume":"17","author":[{"given":"Adeeb","family":"Shehzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauhar","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazhar","family":"Ul-Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed Ahmad","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2012.10.009_bib0005","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.socscimed.2009.03.041","article-title":"Drivers of tuberculosis epidemics: the role of risk factors and social determinants","volume":"68","author":"L\u00f6nnroth","year":"2009","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0010","unstructured":"Global tuberculosis control: a short update to the 2009 report. Geneva, World Health Organization 2009, WHO\/HTM\/TB\/2009.426."},{"key":"10.1016\/j.bjid.2012.10.009_bib0015","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"13","author":"Zhang","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0020","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(09)60331-7","article-title":"Epidemiology of antituberculosis drug resistance 2002\u201307: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance","volume":"373","author":"Wright","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2012.10.009_bib0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1185449","article-title":"The population dynamics and control of tuberculosis","volume":"328","author":"Dye","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0030","first-page":"354","article-title":"Multidrug-resistant tuberculosis","volume":"120","author":"Sharma","year":"2004","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.bjid.2012.10.009_bib0035","first-page":"97","article-title":"Drug resistance in Mycobacterium tuberculosis","volume":"8","author":"Johnson","year":"2006","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1286-4579(00)00359-2","article-title":"The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis","volume":"2","author":"Slayden","year":"2000","journal-title":"Microbes Infect"},{"key":"10.1016\/j.bjid.2012.10.009_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1054\/tuld.1998.0208","article-title":"The molecular basis of isoniazid resistance in Mycobacterium tuberculosis","volume":"79","author":"Heym","year":"1999","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bjid.2012.10.009_bib0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0163-7827(98)00008-3","article-title":"Mycolic acids: structure, biosynthesis and physiological functions","volume":"37","author":"Barry","year":"1998","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.bjid.2012.10.009_bib0060","first-page":"354","article-title":"Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria","volume":"vol. 1","author":"Winder","year":"1982"},{"key":"10.1016\/j.bjid.2012.10.009_bib0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0070","series-title":"Molecular genetics of mycobacteria","first-page":"235","article-title":"Genetics of drug resistance in Mycobacterium tuberculosis","author":"Zhang","year":"2000"},{"key":"10.1016\/j.bjid.2012.10.009_bib0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0080","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.42.9.2443","article-title":"A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia","volume":"42","author":"Marttila","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1365-2958.1996.00133.x","article-title":"Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance","volume":"22","author":"Rouse","year":"1996","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0090","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2012.10.009_bib0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0924-8579(03)00036-0","article-title":"Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996\u20132001). Description of new mutations in the rpoB gene and review of the literature","volume":"21","author":"Herrera","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2012.10.009_bib0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/infdis\/162.1.201","article-title":"Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system","volume":"162","author":"Salfinger","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0110","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1128\/JB.181.7.2044-2049.1999","article-title":"Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"181","author":"Zhang","year":"1999","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tube.2009.01.004","article-title":"Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis","volume":"89","author":"Sheen","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.bjid.2012.10.009_bib0120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0125","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.33.9.1493","article-title":"Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis","volume":"33","author":"Takayama","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0597-567","article-title":"The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol","volume":"3","author":"Telenti","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3349\/ymj.2002.43.1.59","article-title":"Mutations in the embB locus among Korean clinical isolates of Mycobacterium tuberculosis resistant to ethambutol","volume":"43","author":"Lee","year":"2002","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.bjid.2012.10.009_bib0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.44.2.326-336.2000","article-title":"Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis","volume":"44","author":"Ramaswamy","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0145","first-page":"1367","article-title":"Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?","volume":"13","author":"Van Niekerk","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa022928","article-title":"Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru","volume":"348","author":"Mitnick","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0160","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2012.10.009_bib0165","series-title":"The global plan to stop TB 2011\u20132015: transforming the fight towards elimination of tuberculosis","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.bjid.2012.10.009_bib0170","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bjid.2012.10.009_bib0175","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/QAD.0b013e328329148e","article-title":"Clinical experience with the combined use of lopinavir\/ritonavir and rifampicin","volume":"23","author":"L\u2019homme","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2012.10.009_bib0180","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkp263","article-title":"Pharmacokinetic interactions between rifabutin and lopinavir\/ritonavir in HIV-infected patients with mycobacterial co-infection","volume":"64","author":"Khachi","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0185","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/515174","article-title":"Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis","volume":"28","author":"Burman","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0190","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1473-3099(09)70282-8","article-title":"Tuberculosis and diabetes mellitus: convergence of two epidemics","volume":"9","author":"Dooley","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1742395307081502","article-title":"Diabetes and the risk of tuberculosis: a neglected threat to public health?","volume":"3","author":"Stevenson","year":"2007","journal-title":"Chronic Illn"},{"key":"10.1016\/j.bjid.2012.10.009_bib0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ije\/dyp308","article-title":"A consistent log-linear relationship between tuberculosis incidence and body mass index","volume":"39","author":"L\u00f6nnroth","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bjid.2012.10.009_bib0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ncomms1060","article-title":"A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy","volume":"1","author":"Pethe","year":"2010","journal-title":"Nat Commun"},{"key":"10.1016\/j.bjid.2012.10.009_bib0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0225","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.01182-08","article-title":"Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model","volume":"53","author":"Williams","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.1109755","article-title":"A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics","volume":"308","author":"Charest","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0240","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00181-07","article-title":"In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor","volume":"51","author":"Huitric","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0245","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01393-08","article-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue","volume":"53","author":"Haagsma","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0250","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bjid.2012.10.009_bib0255","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0260","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.00766-06","article-title":"Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration","volume":"50","author":"Lounis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0265","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMra1205429","article-title":"Tuberculosis, drug resistance, and the history of modern medicine","volume":"367","author":"Keshavjee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0270","unstructured":"Global Alliance for TB Drug Development. Evaluation of early bactericidal activity in pulmonary tuberculosis. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov [ClinicalTrials.gov identifier NCT00944021]."},{"key":"10.1016\/j.bjid.2012.10.009_bib0275","first-page":"345","article-title":"Linezolid in the treatment of \u2018difficult\u2019 multidrug-resistant tuberculosis","volume":"12","author":"Yew","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bjid.2012.10.009_bib0285","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"The safety, tolerability and early bactericidal activity and pharmacokinetics of PA824 in previously untreated, uncomplicated, sputum smear-positive pulmonary tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0290","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0295","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0300","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.1176667","article-title":"Antibiotics for emerging pathogens","volume":"325","author":"Fischbach","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bjid.2012.10.009_bib0305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.00749-08","article-title":"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development","volume":"53","author":"Van den Boogaard","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0310","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1093\/infdis\/jis034","article-title":"New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future","volume":"205","author":"Lienhardt","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0315","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0320","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","article-title":"Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0325","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2165\/11538170-000000000-00000","article-title":"Drugs in development for tuberculosis","volume":"70","author":"Ginsberg","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2012.10.009_bib0330","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00451-06","article-title":"Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis","volume":"50","author":"Nuermberger","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0335","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.00074-08","article-title":"Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"52","author":"Nuermberger","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0340","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0345","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","article-title":"Exploiting bacterial DNA gyrase as a drug target: current state and perspectives","volume":"92","author":"Collin","year":"2011","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.bjid.2012.10.009_bib0350","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int J Tuberc LungDis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0355","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","author":"Rodr\u00edguez","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2012.10.009_bib0360","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1128\/AAC.47.8.2442-2444.2003","article-title":"Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis","volume":"47","author":"Cynamon","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0365","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bjid.2012.10.009_bib0370","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.10.009_bib0375","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00002018-200427090-00005","article-title":"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies","volume":"27","author":"Gavin","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.bjid.2012.10.009_bib0380","series-title":"Quinolone antimicrobial agents","year":"2003"},{"key":"10.1016\/j.bjid.2012.10.009_bib0385","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.01621-06","article-title":"Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin","volume":"51","author":"Weiner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.10.009_bib0390","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867012002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867012002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T15:59:53Z","timestamp":1595174393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867012002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1413867012002206"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2012.10.009","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}